{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:44:26Z","timestamp":1777351466019,"version":"3.51.4"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01EY032478"],"award-info":[{"award-number":["R01EY032478"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01EY027767"],"award-info":[{"award-number":["R01EY027767"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.exer.2024.110223","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T17:41:41Z","timestamp":1734716501000},"page":"110223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The vectors went in two-by-two: Transduction efficiency and tolerability of dual and triple rAAV vector delivery following intravitreal injection for genome-editing applications"],"prefix":"10.1016","volume":"251","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2999-6281","authenticated-orcid":false,"given":"Rachel L.","family":"Fehrman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina J.","family":"Chern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle P.","family":"Stoltz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Lipinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"May","key":"10.1016\/j.exer.2024.110223_bib1","article-title":"Binocular benefit following monocular subretinal AAV injection in a mouse model of autosomal dominant retinitis pigmentosa (AdRP)","volume":"206","author":"Ahmed","year":"2023","journal-title":"Vis. Res."},{"key":"10.1016\/j.exer.2024.110223_bib2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-Replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.exer.2024.110223_bib3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41434-019-0060-0","article-title":"Factors governing the transduction efficiency of adeno-associated virus in the retinal ganglion cells following intravitreal injection","volume":"26","author":"Cao","year":"2019","journal-title":"Gene Ther."},{"issue":"SEP","key":"10.1016\/j.exer.2024.110223_bib4","article-title":"Evaluating efficiencies of dual AAV approaches for retinal targeting","volume":"11","author":"Carvalho","year":"2017","journal-title":"Front. Neurosci."},{"issue":"SEP","key":"10.1016\/j.exer.2024.110223_bib5","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3389\/fnins.2017.00503","article-title":"Evaluating efficiencies of dual AAV approaches for retinal targeting","volume":"11","author":"Carvalho","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.exer.2024.110223_bib6","author":"Choi"},{"issue":"11","key":"10.1016\/j.exer.2024.110223_bib8","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/s41551-022-00911-4","article-title":"\u2018Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors\u2019","volume":"6","author":"Davis","year":"2022","journal-title":"Nat. Biomed. Eng."},{"issue":"April","key":"10.1016\/j.exer.2024.110223_bib7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.matbio.2013.10.004","article-title":"Heparan sulfate proteoglycan as a cell-surface endocytosis receptor","volume":"35","author":"Christianson","year":"2014","journal-title":"Matrix Biol."},{"issue":"2","key":"10.1016\/j.exer.2024.110223_bib9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41587-023-01758-z","article-title":"Efficient prime editing in mouse brain, liver and heart with dual AAVs","volume":"42","author":"Davis","year":"2023","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.exer.2024.110223_bib10","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.molmed.2020.09.010","article-title":"Journey to the center of the cell: tracing the path of AAV transduction","volume":"27","author":"Dhungel","year":"2021","journal-title":"Trends Mol. Med."},{"issue":"15","key":"10.1016\/j.exer.2024.110223_bib11","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1016\/S0042-6989(98)00308-3","article-title":"Persistent transgene product in retina, optic nerve and brain after intraocular injection of RAAV","volume":"39","author":"Dudus","year":"1999","journal-title":"Vis. Res."},{"issue":"11","key":"10.1016\/j.exer.2024.110223_bib12","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1089\/hum.2019.132","article-title":"Dual ABCA4-AAV vector treatment reduces pathogenic retinal A2E accumulation in a mouse model of autosomal recessive stargardt disease","volume":"30","author":"Dyka","year":"2019","journal-title":"Hum. Gene Ther."},{"issue":"December","key":"10.1016\/j.exer.2024.110223_bib13","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.omtn.2022.09.013","article-title":"Expanding CRISPR repertoire using CjCas9 as a smaller editing tool","volume":"30","author":"Francis","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"1","key":"10.1016\/j.exer.2024.110223_bib14","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/sj.mt.6300322","article-title":"A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner","volume":"16","author":"Ghosh","year":"2008","journal-title":"Mol. Ther. : The J. Am. Soc. Gene Therapy"},{"issue":"1","key":"10.1016\/j.exer.2024.110223_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/hum.2010.122","article-title":"Efficient transgene reconstitution with hybrid dual AAV vectors carrying the minimized bridging sequences","volume":"22","author":"Ghosh","year":"2011","journal-title":"Hum. Gene Ther."},{"issue":"15","key":"10.1016\/j.exer.2024.110223_bib16","doi-asserted-by":"crossref","first-page":"9933","DOI":"10.1128\/JVI.79.15.9933-9944.2005","article-title":"Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps","volume":"79","author":"Grieger","year":"2005","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.exer.2024.110223_bib17","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3390\/cells12030440","article-title":"Future perspectives of prime editing for the treatment of inherited retinal diseases","volume":"12","author":"Hansen","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.exer.2024.110223_bib18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.coviro.2014.05.007","article-title":"Parvovirus glycan interactions","volume":"7","author":"Huang","year":"2014","journal-title":"Curr. Opin. Virol."},{"issue":"2","key":"10.1016\/j.exer.2024.110223_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41551-021-00788-9","article-title":"Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases","volume":"6","author":"Jang","year":"2021","journal-title":"Nat. Biomed. Eng."},{"issue":"2","key":"10.1016\/j.exer.2024.110223_bib20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41551-021-00788-9","article-title":"\u2018Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases\u2019","volume":"6","author":"Jang","year":"2021","journal-title":"Nat. Biomed. Eng."},{"issue":"10","key":"10.1016\/j.exer.2024.110223_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax1210","article-title":"CRISPR-Cas9\u2013Mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of leber congenital amaurosis","volume":"5","author":"Jo","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.exer.2024.110223_bib22","article-title":"Therapeutic adenine base editing corrects nonsense mutation and improves visual function in a mouse model of leber congenital amaurosis","author":"Jo","year":"2021","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.exer.2024.110223_bib23","first-page":"1","article-title":"In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni","volume":"8","author":"Kim","year":"2017","journal-title":"Nat. Commun."},{"issue":"February","key":"10.1016\/j.exer.2024.110223_bib24","article-title":"In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni","volume":"8","author":"Kim","year":"2017","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.exer.2024.110223_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1607","article-title":"Optimization strategies and advances in the research and development of AAV-based gene therapy to deliver large transgenes","volume":"14","author":"Kolesnik","year":"2024","journal-title":"Clin. Transl. Med."},{"issue":"7","key":"10.1016\/j.exer.2024.110223_bib26","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrg3742","article-title":"Engineering adeno-associated viruses for clinical gene therapy","volume":"15","author":"Kotterman","year":"2014","journal-title":"Nat. Rev. Genet."},{"issue":"3","key":"10.1016\/j.exer.2024.110223_bib27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/d41573-021-00017-7","article-title":"The clinical landscape for AAV gene therapies","volume":"20","author":"Kuzmin","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.exer.2024.110223_bib28","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1089\/hum.2006.17.1036","article-title":"Synthetic intron improves transduction efficiency of trans-splicing adeno-associated viral vectors","volume":"17","author":"Lai","year":"2006","journal-title":"Hum. Gene Ther."},{"issue":"December","key":"10.1016\/j.exer.2024.110223_bib29","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.12688\/f1000research.11243.1","article-title":"In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease","volume":"6","author":"Lau","year":"2017","journal-title":"F1000Research"},{"issue":"1","key":"10.1016\/j.exer.2024.110223_bib48","article-title":"OPA1: 516 unique variants and 831 patients registered in an updated centralized variome database. Orphanet","volume":"14","author":"Le Roux","year":"2019","journal-title":"J. Rare Dis."},{"issue":"4","key":"10.1016\/j.exer.2024.110223_bib30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"10.1016\/j.exer.2024.110223_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"September","key":"10.1016\/j.exer.2024.110223_bib32","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.omtn.2021.06.020","article-title":"Modeling a cataract disorder in mice with prime editing","volume":"25","author":"Lin","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"1","key":"10.1016\/j.exer.2024.110223_bib33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.preteyeres.2012.09.001","article-title":"Clinical applications of retinal gene therapy","volume":"32","author":"Lipinski","year":"2013","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.exer.2024.110223_bib34","article-title":"Efficient rescue of retinal degeneration in Pde6a mice by engineered base editing and prime editing","author":"Liu","year":"2024","journal-title":"Adv. Sci."},{"issue":"8","key":"10.1016\/j.exer.2024.110223_bib35","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/gt.2013.3","article-title":"Retinal gene therapy with a large MYO7A CDNA using adeno-associated virus","volume":"20","author":"Lopes","year":"2013","journal-title":"Gene Ther."},{"issue":"1","key":"10.1016\/j.exer.2024.110223_bib36","first-page":"160","article-title":"\u2018Identification of RPGR ORF15 mutation for X-linked retinitis pigmentosa in a large Chinese family and in vitro correction with prime editor\u2019","volume":"30","author":"Lv","year":"2022","journal-title":"Gene Ther."},{"issue":"2","key":"10.1016\/j.exer.2024.110223_bib37","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ymthe.2017.11.019","article-title":"Triple vectors expand AAV transfer capacity in the retina","volume":"26","author":"Maddalena","year":"2018","journal-title":"Mol. Ther. : The J. Am. Soc. Gene Therapy"},{"issue":"2","key":"10.1016\/j.exer.2024.110223_bib38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-018-0327-9","article-title":"Development of a gene-editing approach to restore vision loss in leber congenital amaurosis type 10","volume":"25","author":"Maeder","year":"2019","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.exer.2024.110223_bib39","doi-asserted-by":"crossref","DOI":"10.4172\/2157-7412.1000311","article-title":"A fragmented adeno-associated viral dual vector strategy for treatment of diseases caused by mutations in large genes leads to expression of hybrid transcripts","volume":"7","author":"McClements","year":"2016","journal-title":"J. Genet. Syndr. Gene Ther."},{"issue":"7","key":"10.1016\/j.exer.2024.110223_bib40","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1167\/tvst.9.7.20","article-title":"Assessment of AAV dual vector safety in the Abca4\u2212\/\u2212 mouse model of stargardt disease","volume":"9","author":"McClements","year":"2020","journal-title":"Translational Vision Science & Technology"},{"issue":"6","key":"10.1016\/j.exer.2024.110223_bib41","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41434-022-00380-z","article-title":"Improving adeno-associated viral (AAV) vector-mediated transgene expression in retinal ganglion cells: comparison of five promoters","volume":"30","author":"Nieuwenhuis","year":"2023","journal-title":"Gene Ther."},{"issue":"5","key":"10.1016\/j.exer.2024.110223_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0285370","article-title":"Improving retinal vascular endothelial cell tropism through rational RAAV capsid design","volume":"18","author":"Periasamy","year":"2023","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.exer.2024.110223_bib43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/hgtb.2014.120","article-title":"Development of a rapid, robust, and universal picogreen-based method to titer adeno-associated vectors","volume":"26","author":"Piedra","year":"2015","journal-title":"Hum. Gene Ther. Methods"},{"issue":"7588","key":"10.1016\/j.exer.2024.110223_bib44","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature16465","article-title":"An essential receptor for adeno-associated virus infection","volume":"530","author":"Pillay","year":"2016","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.exer.2024.110223_bib45","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220776","article-title":"Vision rescue via unconstrained in vivo prime editing in degenerating neural retinas","volume":"220","author":"Qin","year":"2023","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.exer.2024.110223_bib46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-1-4939-7522-8_2","article-title":"Small and micro-scale recombinant adeno-associated virus production and purification for ocular gene therapy applications","volume":"1715","author":"Reid","year":"2018","journal-title":"Methods Mol. Biol."},{"issue":"14","key":"10.1016\/j.exer.2024.110223_bib47","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.1167\/iovs.17-22281","article-title":"Improvement of photoreceptor targeting via intravitreal delivery in mouse and human retina using combinatory RAAV2 capsid mutant vectors","volume":"58","author":"Reid","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.exer.2024.110223_bib49","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/hum.2006.17.10","article-title":"Adeno-associated virus types 5 and 6 Use distinct receptors for cell entry","volume":"17","author":"Seiler","year":"2006","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"10.1016\/j.exer.2024.110223_bib50","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41392-022-01234-1","article-title":"Dual-AAV split prime editor corrects the mutation and phenotype in mice with inherited retinal degeneration","volume":"8","author":"She","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"15","key":"10.1016\/j.exer.2024.110223_bib51","doi-asserted-by":"crossref","first-page":"13532","DOI":"10.1074\/jbc.M110.210922","article-title":"Terminal N-linked galactose is the primary receptor for adeno-associated virus 9","volume":"286","author":"Shen","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.exer.2024.110223_bib52","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/mt.2009.277","article-title":"Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 Years after vector administration","volume":"18","author":"Simonelli","year":"2010","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.exer.2024.110223_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1566523221666211006120355","article-title":"CRISPR systems suitable for single AAV vector delivery","volume":"22","author":"Stevanovic","year":"2021","journal-title":"Curr. Gene Ther."},{"issue":"2","key":"10.1016\/j.exer.2024.110223_bib54","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1128\/JVI.72.2.1438-1445.1998","article-title":"Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions","volume":"72","author":"Summerford","year":"1998","journal-title":"J. Virol."},{"issue":"492","key":"10.1016\/j.exer.2024.110223_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav4523","article-title":"Intein-mediated protein trans-splicing expands adeno-associated virus transfer capacity in the retina","volume":"11","author":"Tornabene","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"R1","key":"10.1016\/j.exer.2024.110223_bib56","doi-asserted-by":"crossref","first-page":"R108","DOI":"10.1093\/hmg\/ddz130","article-title":"Has retinal gene therapy come of age? From bench to bedside and back to bench","volume":"28","author":"Trapani","year":"2019","journal-title":"Hum. Mol. Genet."},{"issue":"2","key":"10.1016\/j.exer.2024.110223_bib57","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/emmm.201302948","article-title":"Effective delivery of large genes to the retina by dual AAV vectors","volume":"6","author":"Trapani","year":"2014","journal-title":"EMBO Mol. Med."},{"issue":"13","key":"10.1016\/j.exer.2024.110223_bib58","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1093\/nar\/gkv601","article-title":"Development of an intein-mediated split\u2013cas9 system for gene therapy","volume":"43","author":"Truong","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.exer.2024.110223_bib59","article-title":"Rational design of a compact CRISPR-cas9 activator for AAV-mediated delivery","author":"Vora","year":"2018","journal-title":"bioRxiv"},{"issue":"January","key":"10.1016\/j.exer.2024.110223_bib60","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.visres.2016.10.012","article-title":"Evaluating outer segment length as a surrogate measure of peak foveal cone density","volume":"130","author":"Wilk","year":"2017","journal-title":"Vis. Res."},{"issue":"January","key":"10.1016\/j.exer.2024.110223_bib61","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.visres.2016.10.012","article-title":"Evaluating outer segment length as a surrogate measure of peak foveal cone density","volume":"130","author":"Wilk","year":"2017","journal-title":"Vis. Res."},{"key":"10.1016\/j.exer.2024.110223_bib62","series-title":"OPA1 Dominant Optic Atrophy: Pathogenesis and Therapeutic Targets","author":"Wong","year":"2023"},{"issue":"May","key":"10.1016\/j.exer.2024.110223_bib63","article-title":"The internal limiting membrane: roles in retinal development and implications for emerging ocular therapies","volume":"206","author":"Zhang","year":"2021","journal-title":"Exp. Eye Res."},{"issue":"3\u20134","key":"10.1016\/j.exer.2024.110223_bib64","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41434-022-00359-w","article-title":"RAAV-mediated over-expression of acid ceramidase prevents retinopathy in a mouse model of farber lipogranulomatosis","volume":"30","author":"Zhang","year":"2023","journal-title":"Gene Ther."},{"issue":"1","key":"10.1016\/j.exer.2024.110223_bib65","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ymthe.2021.07.011","article-title":"Dual-AAV delivering split prime editor system for in vivo genome editing","volume":"30","author":"Zhi","year":"2021","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.exer.2024.110223_bib66","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ymthe.2021.07.011","article-title":"Dual-AAV delivering split prime editor system for in vivo genome editing","volume":"30","author":"Zhi","year":"2022","journal-title":"Mol. Ther."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483524004457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483524004457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:20:00Z","timestamp":1777350000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483524004457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":66,"alternative-id":["S0014483524004457"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2024.110223","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The vectors went in two-by-two: Transduction efficiency and tolerability of dual and triple rAAV vector delivery following intravitreal injection for genome-editing applications","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2024.110223","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110223"}}